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We have analyzed the effect of transfection into murine NIH/3T3 cells of the human dsRNA-activated kinase PKR on the
expression of the b-galactosidase reporter gene, placed under control of the HIV1 or the HTLV-I LTR. b-Galactosidase
expression is stimulated when the reporter plasmids are cotransfected with wild-type PKR but inhibited when cotransfected
with a catalytically inactive mutant PKR. In the case of HIV1, b-galactosidase expression was not stimulated when cotransfec-
tion was carried out with PKR harboring mutations in the dsRNA binding domains, indicating that stimulation depends on
the classical mode of PKR activation through dsRNA binding. In contrast, the dsRNA binding mutants of PKR could still
partially stimulate b-galactosidase expression from the HTLV-I LTR, suggesting that PKR activation in this case may involve
different/additional mechanisms. These results show that, in addition to the known down-regulation of protein synthesis
through eIF2 phosphorylation, PKR can also positively stimulate gene expression in vivo, most probably through phosphoryla-
tion of a substrate distinct from eIF2. q 1995 Academic Press, Inc.
The double-stranded RNA-activated protein kinase wt PKR, these results collectively demonstrated that mu-
tant PKR can function as a dominant oncogene (6). ItPKR is a serine/threonine kinase that is present at basal
levels in most cells and can be induced after interferon is not clear whether this latter function involves eIF2
phosphorylation or if another substrate is required. Intreatment. The function of PKR is regulated by the pres-
ence in the cells of dsRNA molecules, ssRNA presenting this regard, it has been recently demonstrated that PKR
can also phosphorylate IkB, the NF-kB inhibitor, thusinternal dsRNA regions or other polyanionic molecules
(1). Once activated by dsRNA, which triggers its auto- liberating NF-kB activity and implicating PKR in the signal
transduction pathway of specific genes (7, 8).phosphorylation, PKR phosphorylates the a subunit of
the initiation factor eIF2, leading to inhibition of protein Since PKR binds to, and can be activated by, double-
stranded RNA molecules, it represents an importantsynthesis (2, 3).
PKR plays an important role in the antiviral and antipro- threat for many viruses that synthesize and are depen-
dent on double-stranded RNA for replication and tran-liferative actions of interferon. Cell lines expressing the
wt PKR caused partial inhibition of encephalomyocarditis scription. Systematic analysis of the relationship be-
tween viruses and PKR has revealed that many virusesvirus replication. This inhibition, which was not observed
in cell lines expressing a catalytically inactive mutant of can specifically escape or counteract PKR action. For
instance, inhibition of PKR can be obtained (a) by directPKR, coincided with in vivo phosphorylation of both PKR
and its substrate, eIF2. Thus, PKR can be directly impli- binding to high concentrations of viral dsRNA [adenovi-
rus VA1 (9), Epstein–Barr EBERs (10)], (b) by competitioncated in one of the mechanisms leading to the antiviral
action of interferon (4). In addition, a cell line expressing with viral proteins for the dsRNA activator [vaccinia E3L
protein (11), reovirus s3 protein (12)], (c) by interferencea mutant of PKR, lacking the eIF2 binding region (5), and
cell lines constitutively expressing catalytically inactive in the interaction with the substrate eIF2 [vaccinia K3L
protein (13)], (d) by virus-induced synthesis of cellularmutant PKR developed tumors in nude mice. Because
tumors were not formed by injection of cells expressing protein inhibitors for PKR [poliovirus-induced cellular pro-
tease (14), influenza virus-induced TPRp58 (15)], or (e)
by PKR compartmentalization [EMCV (16)].1 To whom correspondence and reprint requests should be ad-
The interactions between PKR and HIV1 have alsodressed at Unite´ de Virologie et d’Immunologie Cellulaire, Institut
been analyzed in some detail. All HIV mRNAs contain aPasteur, 25,rue du Dr. Roux, 75724 Paris Cedex 15, France. Fax: 33 1
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untranslated leader sequence, which is transcribed with of expression of PKRwt in clone 68.11 and PKRK-R296 in
the TAR region of the LTR and located downstream of clone 12.3 compared with the control NIH/3T3 clone
the site of transcription initiation. Below the loop, there (Neo) are shown in Fig. 2C. Transfection of pJK2 into
is a three-nucleotide bulge which is necessary for the these clones resulted in higher expression of b-galactos-
binding of the HIV1 transactivating Tat protein. The size idase in the clone 68.11 expressing PKRwt than in the
of the double-stranded stem structure of TAR is suffi- control clone Neo and much lower expression in the
ciently long to cause activation of PKR but different exper- clone 12.3 expressing the catalytically inactive PKRK-R296
imental studies have yielded controversial results. Al- (Fig. 2D). These findings therefore are in accord with
though it has been clearly demonstrated that TAR binds the results obtained from cotransfections and indicate
to PKR in vitro (17), there are conflicting reports on clearly that PKR is functionally involved in this process.
whether TAR mediates transinhibition of translation PKR consists of two domains, a catalytic domain, lo-
through activation of PKR and subsequent eIF2 phos- cated in the carboxy-terminal part of the protein, which
phorylation (18 – 21) or behaves as an inhibitor of PKR is responsible for the kinase activity (26), and a regulatory
by sequestration, like VA1 or EBER RNAs (22, 23). The domain, located in the amino-terminal part of the protein.
experiments indicating TAR-activation of PKR were all The regulatory domain comprises two basic dsRNA bind-
performed in vitro while the experiments concluding that ing motifs (27, 28) and a third basic domain which does
TAR inhibited PKR also involved in vivo transfection not bind dsRNA but is required for PKR activity (29, 30).
assays. However, all of the latter transfection experi- Mutation analysis by deletion or by amino acid substitu-
ments were based on expression of a reporter gene cou- tion has defined the amino acids that are critical for
pled to, or transfected in the presence of, TAR RNA and dsRNA binding. Specifically, three amino acids (G57, K60,
did not deal directly with PKR (22, 23). and K64) of the first dsRNA binding domain
In this study, we investigated the effect of PKR on (G57RSK60KEAK64NAAAKLAVEIL) are essential for dsRNA-
the expression of a reporter gene (nuclear-targeted b- binding of PKR in vitro and expression of a growth sup-
galactosidase), placed directly under the control of the pressor phenotype in yeast (31, 32). To determine
LTR region of HIV1 (24), by transient transfections with whether the stimulation of b-galactosidase expression
different coding sequences for the human PKR. We have from the HIV1 LTR was specifically mediated by PKR,
compared the properties of the native enzyme (PKRwt) through its activation by dsRNA, we analyzed the expres-
with a catalytically inactive mutant (PKRK-R296) and single sion of the HIV1 LTR–b-galactosidase in the presence
substitution mutants in the first dsRNA binding domain
of three PKRdsRNA0 mutants: PKRG-A57, PKRK-A60, and PKRK-A64.
of the kinase (PKRG-A57, PKRK-A60, and PKRK-A64). The re-
The results (Fig. 3) show that the expression of b-galac-
sults show that PKR is able to stimulate gene expression
tosidase is reduced in the presence of the three
from the HIV1 LTR. Similarly, we also show that PKR is
PKRdsRNA0 mutants. These data clearly establish that theable to stimulate gene expression from the HTLV-I LTR.
stimulation of b-galactosidase observed when pJK2 isIn order to observe data resulting exclusively from the
coexpressed with PKRwt is related to activation of PKRsimultaneous presence of the LTRs and the different PKR
from binding to dsRNA molecules.constructs (Fig. 1), we have chosen to perform our assays
We have also examined whether the PKR-induced stimu-in murine NIH/3T3 cells since these cells contain ex-
lation of gene expression observed for the HIV1 LTR couldtremely low levels of endogenous PKR (25). Although
apply to other promoters. Similar cotransfection experi-expression of the HIV1 LTR is much lower in murine cells
ments were carried out using constructs in which the HIV1than in human cells, preliminary experiments indicated
LTR was replaced with the HTLV-I LTR or with the CMVthat expression from the pJK2 plasmid could be reproduc-
immediate-early promoter upstream of theb-galactosidaseibly detected in NIH/3T3 cells. When the PKR plasmids
gene. The results (Fig. 4A) show that PKRwt stimulates, andwere coprecipitated with either 0.5 or 1.5 mg of pJK2, we
catalytically inactive PKRK-R296 inhibits, the expression of b-observed that b-galactosidase expression was en-
galactosidase under the control of HTLV-I LTR, similar tohanced by PKRwt but inhibited in the presence of the
the results obtained for the HIV1 LTR. However, when wecatalytically inactive mutant PKRK-R296 (Fig. 2A). Increasing
examined the PKRdsRNA0 mutants, we found, in contrast toamounts of the PKRwt plasmid (0.5 to 3 mg) cotransfected
the HIV1 LTR, that all three mutants stimulated expressionwith 0.5 mg of pJK2 gradually increased the stimulation
of b-galactosidase from the HTLV-I LTR, although to aof expression of pJK2 with a maximum of threefold stimu-
lesser extent than PKRwt. When the reporter gene waslation obtained for 3 mg of DNA. On the other hand,
placed under the control of the CMV promoter, there wasincreasing the concentration of PKRK-R296 gradually inhib-
less striking regulation of expression by PKR. Moreover,b-ited the basal expression of pJK2 to a maximum of two-
galactosidase expression was not inhibited in the presencefold inhibition (Fig. 2B).
of PKRK-R296 (Fig. 4B). Therefore, we conclude that a func-To confirm this observation, we directly examined the
tional PKR can specifically stimulate the expression ofexpression of pJK2 in NIH/3T3 clones constitutively ex-
pressing the human PKRwt or the PKRK-R296 (4). The levels genes placed under the control of the HIV1 and HTLV-I
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FIG. 1. Schematic representation of the different plasmids used for transfection. The plasmids pJK2 and pCMV-tat have been described previously
(24). Briefly, pJK2 contains a truncated HIV1 LTR (0138 to /83 or ScaI to HindIII) followed by the complete b-galactosidase gene modified at its
5* end to contain the nuclear targeting sequence of the SV40 T antigen. The plasmid pHTLV-I-bgal, corresponding to pJK2 but with the HTLV-I
promoter instead of the HIV promoter, was constructed as follows: the plasmid HTLV-oligophX (35) containing the HTLV-I LTR of HTLV-I and the
tax region (a gift from M. Nerenberg) was cut with XhoI and HindIII to yield the LTR from 1 to 713 bp. This fragment was ligated into the pEQJK
plasmid cut with HindIII and Sal I. The plasmid pEQJK corresponds to the pJK2 plasmid but with a polylinker region 5* of the nuclear-targeted b-
galactosidase gene instead of the HIV promoter. To construct the plasmid pCMV-bgal, the CMV promoter was cut from the pCMV-tat plasmid with
HindIII and XbaI and inserted between these sites in the polylinker region of plasmid pEQJK. The PKRwt gene and its catalytically inactive mutant
PKRK-R296 form have been described previously (4, 6). In this study, the genes were expressed from the pcDNA/Amp vector instead of the pcDNA/
neo vector. The pcDNA/neo vectors that express PKR mutants with altered dsRNA-binding properties have been recently described (32). Each of these
mutants differs from PKRwt by a single amino acid substitution Gly to Ala (PKRG-A57) and Lys to Ala (PKRK-A60, PKRK-A64) in the carboxy-terminal region
(G57RSK60KEAK64NAAKLAVEIL) of the dsRNA-binding domain I of PKR. Such mutants do not bind (PKRG-A57, PKRK-A60), or bind poorly (PKRK-A64),
to dsRNA in vitro and cannot become activated (32). For PKR plasmids, the regulatory domain and the catalytic domains are represented in gray
and hatched boxes, respectively. The catalytic subdomain II involved in the transfer of phosphate is inactivated by substitution of the lysine residue
(Lys296 in PKRwt) to arginine (Arg296 in PKRK-R296). The carboxy-terminal part of dsRNA binding domain I (R1 domain) is indicated (residues 57 to
75) and the different substitutions to alanine residues leading to abrogation of dsRNA binding are indicated for the PKRdsRNA0 mutants. For the
reporter plasmids, the nuclear-localizing sequence from the SV40 T antigen and the b-galactosidase sequence are represented by a black box and
a white box, respectively.
LTRs, whereas the CMV promoter is not affected by this to bind to, and be activated by, the HTLV-I Rex-response
element in in vitro experiments (33). The Rex-responsesame regulatory mechanism.
The structure of the activator for PKR-mediated stimula- element is located in the U3/R of the HTLV-I LTR and
presents a highly dsRNA secondary structure which istion from the HTLV-I LTR remains to be determined. By
analogy with the dsRNA TAR region of HIV1, which is essential for rex regulation when expressed on the 3* end
of mRNAs (34). Since the CAP site is located within theknown to bind PKR, it is possible that the 5* untranslated
sequence of the RNAs transcribed from the HTLV-I LTR Rex-response element, transcripts from the HTLV-I LTR
also contain part of the Rex-response element, althoughalso contains a dsRNA structure capable of binding and
activating PKR. Indeed, recently, PKR has been reported deleted from its first 40 bases, involved in the formation
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FIG. 2. Regulation of the expression of HIV1 LTR b-galactosidase by PKR. NIH/3T3 (Neo) cells were plated (3 1 105 cells) in 35-mm-diameter
dishes in DMEM with 10% fetal calf serum, 18 to 24 hr before transfection. The medium was aspirated and replaced with fresh medium (4 ml per
well) 3 hr before transfection. The desired amounts of plasmids were adjusted to the same final concentration of DNA by addition of pcDNA/Neo
DNA, mixed in 250 ml of water before adding CaCl2 to 250 mM and the resulting DNA/CaCl2 solution was added dropwise to 250 ml of 21 HBS
buffer (50 mM HEPES, 270 mM NaCl, 2.8 mM Na2HPO4 , pH 7.11) while vortexing continuously. The DNA/calcium phosphate precipitate was added
directly to the medium and the plates were incubated at 377 for 3 to 4 hr. The medium was removed and the cells were washed once with serum-
free medium and overlaid for 2 min with 1 ml of 15% glycerol/11 HBS buffer. The cells were washed twice with complete medium and the plates
were further incubated in complete medium for 48 hr at 377. The expression of b-galactosidase was then measured by directly counting the cells
expressing the enzyme: the medium was removed, the cells were washed once with phosphate-buffered saline (PBS) and fixed at room temperature
with 1 ml of a solution of 1% formaldehyde–0.2% glutaraldehyde in PBS for 5 min. The cells were then washed three times with PBS and incubated
for 50 min at 377 in 500 ml of a solution (in water) of 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM MgCl2 , and 0.4 mg of X-
Gal/ml. The reaction was stopped by removing the staining solution and washing the cells twice with PBS. Blue cells were counted under a
microscope with a magnification of 120 (24). In A, 3 mg of PKRwt or PKRK-R296 was cotransfected with 0.5 or 1.5 mg of pJK2. In B, the pJK2 concentration
was kept constant (0.5 mg) and the concentration of the PKR plasmids varied (0.5, 1, 2, and 3 mg). (C) Constitutive expression of human PKRwt and
PKRK-R296 in murine NIH/3T3 cell lines. The NIH/3T3 clones expressing either pcDNA/Neo alone (clone Neo) or pcDNA/Neo carrying the wt PKR
(clone 68.11) or the PKRK-R296 mutated in its subcatalytic subdomain II by a substitution from Lys to Arg (clone 12.3) have been described previously
(4). Cells were grown in DMEM containing 10% fetal calf serum in the presence of 400 mg/ml G418 (geneticin; Gibco). Cells were washed and scraped
in PBS, pelleted by centrifugation and proteins were extracted with 10 mM Tris–HCl, pH 7.6, 10 mM KCl, 1 mM EDTA, 7 mM 2-mercaptoethanol, 0.5%
Triton X-100, 0.2 mM phenylmethylsulfonylfluoride (PMSF), 10 mg/ml aprotinin, 10 mg/ml leupeptin. After 10 min at 47, the extracts were diluted twice
with B.I buffer (20 mM Tris–HCl, pH 7.6, 50 mM KCl, 400 mM NaCl, 1 mM EDTA, 1% Triton X-100, 5 mM 2-mercaptoethanol, 0.2 mM PMSF, 10 mg/
ml aprotinin, 10 mg/ml leupeptin, 20% glycerol) and centrifuged at 12,000 g, and the supernatants were aliquoted and frozen at 0807. For immunoblot
analysis, the cytoplasmic protein extracts, corresponding to 2 1 106 cells, were separated by SDS–PAGE in 12.5% polyacrylamide gels, transferred
to Immobilon-P membranes (Millipore), and incubated with polyclonal antibodies to PKR (26) and anti-mouse immunoglobulin coupled to horseradish
peroxidase (ECL; Amersham). PKR was visualized after incubation with ECL reagents and exposure to X-ray film (Kodak). (D) Two micrograms of
pJK2 was transfected into the different clones, Neo, 68.11, or 12.3.
of its two major stems. It is possible that, as such, the and PKRK-A64, were still partially functional in stimulating
the LTR from HTLV-I raises questions about the mecha-Rex-response element refolds in a different secondary
structure sufficient to allow the in vivo activation of PKR nism of activation. Whatever the nature of the activator for
HTLV-I, it must either interact with amino acid residues inthat we have observed. On the other hand, the fact that
the three PKR dsRNA binding mutants, PKRG-A57, PKRK-A60, the dsRNA binding domain I of PKR other than glycine57,
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FIG. 3. The stimulation of HIV1 LTR by PKR depends on a functional dsRNA binding region in the regulatory domain of the enzyme. The murine
NIH/3T3 (Neo) cells were transfected with 0.5 mg of pJK2 in the presence of 3 mg of PKRwt, the catalytically inactive mutant PKRK-R296, or each of
the three dsRNA0 mutants: PKRG-A57, PKRK-A60, and PKRK-A64. Forty-eight hours after transfection, the expression of b-galactosidase was assayed as
described under Fig. 2.
lysine60, or lysine64 or, alternatively, it may interact with vector could be activated on domains other than those
required for binding dsRNA (30).activation domains of PKR other than domain I. In this
regard, it has been recently reported that a dsRNA binding Here, we have shown that direct expression of PKR
affects the expression of a reporter gene under the con-mutant of PKR expressed in vivo from a vaccinia virus
FIG. 4. PKR specifically stimulates the expression of genes placed under the control of the HTLV-I LTR but not under the control of the CMV immediate-
early promoter. The murine NIH/3T3 (Neo) cells were transfected with (A) 0.5 mg of pHTLV-I–b-galactosidase or with (B) 0.5 mg of pCMV-b galactosidase
in the presence of 3 mg of PKRwt, the catalytically inactive mutant PKRK-R296, or each of the three dsRNA0 mutants: PKRG-A57, PKRK-A60, and PKRK-A64. Forty-
eight hours after transfection, the expression of b-galactosidase was assayed as described under Fig. 2.
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trol of the LTR from HIV1. In the presence of the wild- tion. Attempts to detect NF-kB activation by gel-shift
assay were inconclusive. Cell extracts from doublytype PKR, expression from the LTR was stimulated. Ex-
pression was unchanged in the presence of PKRdsRNA0 transfected NIH/3T3 cells did not contain any detectable
NF-kB activity, most probably due to lack of sensitivitymutants and inhibited when cotransfection was carried
out with the catalytically inactive mutant PKRK-R296. The in the experiment since only a small number of cells are
expressing both PKR and the HIV1 LTR promoter (datadata with PKRwt and with PKRdsRNA0 mutants, taken to-
gether, strongly suggest that PKR has been activated in not shown). In the clone constitutively expressing PKRwt,
NF-kB was found to be active constitutively, masking thevivo, most probably by the TAR region of the LTR of HIV1
since this region has previously been shown to activate observation of any possible increase after transfection
with the HIV LTR plasmid (data not shown). The develop-PKR (20, 21). It should be emphasized, however, that our
in vivo assay does not allow one to test whether PKR ment, however, of an expression system based on condi-
tional expression of PKR should allow this question toactivation was dependent on TAR and thus we cannot
exclude a possible contribution from other potential be addressed directly. There is also a possibility that the
substrate involved in the stimulation of genes expresseddsRNA structures in the HIV1 LTR distinct from TAR.
The data for cotransfection with PKRwt are also consis- from the HIV1 LTR acts at a posttranscriptional level,
favoring, for example, the stabilization of the new tran-tent with experiments reported previously showing stimu-
lation of expression of a reporter gene cotransfected with scripts or their ability to be correctly translated.
Thus PKR, in addition to having the ability to regulatea TAR-expressing vector (22, 23). In this latter case, stim-
ulation was explained as resulting from the sequestration gene expression at the translational level through eIF2
phosphorylation, can also be involved in the stimulationof PKR by high inhibitory levels of TAR RNA and the
consequential failure of PKR to regulate the initiation of of gene expression. Dual regulation of both translation
and transcription by PKR in virus-infected cells is likelyprotein synthesis through eIF2 phosphorylation. There-
fore, the stimulation of expression should occur indepen- to be important in determining the activation state of HIV1
and HTLV-I genomes and may influence the progressiondently of the nature—wild type or catalytically inactive
mutant—of the sequestered PKR. Since our data from latent to productive infections.
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